Dechra Pharmaceuticals PLC
DPHAY
Other OTC98.00
USD
+1.90
- -
ISIN
US2434351043
Return %
Stock
S&P500
1Y
31.92
18.44
3Y
41.01
63.65
5Y
44.12
74.90
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Ian D. Page
- Full Time Employees
- 2,457
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 24 Cheshire Avenue Northwich United Kingdom CW9 7UA
- IPO Date
- Feb 26, 2018
- Website
- dechra.com
- Similar Companies
- Business
- Dechra Pharmaceuticals PLC (DPHAY) is a global specialist in the development, manufacture, marketing and sales of high-quality veterinary pharmaceuticals and related products exclusively for veterinarians worldwide. The company offers a broad portfolio of innovative and differentiated products across niche therapeutic areas including endocrinology, topical dermatology, anaesthesia, pain and inflammation management, equine lameness treatment, nutrition and generics; key offerings encompass companion animal products such as Vetoryl capsules for endocrinology, alongside water-soluble antibiotics, poultry vaccines, pain management solutions for poultry, pigs and cattle, and pet care items. It operates through direct salesforces in approximately 25 countries and distributors in over 60 others, targeting veterinarians in companion animal, equine and livestock segments primarily in Europe, North America and internationally. Founded in 1997 and headquartered in Northwich, Cheshire, United Kingdom, Dechra was delisted from the London Stock Exchange in January 2024 and taken private by an EQT-led consortium. Recent developments include the July 2024 announcement of its acquisition of Invetx for up to $520 million to gain a pipeline of species-specific monoclonal antibody therapeutics for chronic companion animal conditions like atopic dermatitis and osteoarthritis, enhancing its biotechnology capabilities and innovation leadership.